Published in J Acquir Immune Defic Syndr on July 01, 2011
Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. AIDS (2012) 1.41
Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania. AIDS Patient Care STDS (2011) 1.01
Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril (2012) 0.96
Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS (2013) 0.92
25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis (2014) 0.92
Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve. Int J Endocrinol (2013) 0.90
Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS One (2014) 0.88
Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals. Curr HIV/AIDS Rep (2012) 0.86
Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. J Clin Endocrinol Metab (2013) 0.83
Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants. AIDS Patient Care STDS (2013) 0.80
Risk factors for vitamin D deficiency among veterans with and without HIV infection. PLoS One (2015) 0.80
Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc (2014) 0.79
Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses (2012) 0.79
Vitamin D and bone loss in HIV. Curr Opin HIV AIDS (2016) 0.78
Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis (2012) 0.78
Low vitamin D status among pregnant Latin American and Caribbean women with HIV Infection. Int J Gynaecol Obstet (2015) 0.77
Vitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected Individuals. J AIDS Clin Res (2012) 0.77
Risk factors for vitamin D deficiency among HIV-infected and uninfected injection drug users. PLoS One (2014) 0.77
Prevalence and Factors Associated with Vitamin D Deficiency and Hyperparathyroidism in HIV-Infected Patients Treated in Barcelona. ISRN AIDS (2012) 0.77
Vitamin D, bone, and HIV infection. Top Antivir Med (2012) 0.76
Short communication: High prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women. AIDS Res Hum Retroviruses (2013) 0.76
Association among vitamin D, oral candidiasis, and calprotectinemia in HIV. J Dent Res (2012) 0.76
Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study. AIDS Res Hum Retroviruses (2016) 0.75
Contribution of vitamin D(2) to total vitamin D in HIV-positive patients. J Acquir Immune Defic Syndr (2011) 0.75
Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers. Curr Ther Res Clin Exp (2014) 0.75
Vitamin D deficiency in HIV-infected and -uninfected women in the United States. J Acquir Immune Defic Syndr (2012) 0.75
Number of Primary Care Visits Associated with Screening for Cervical Dysplasia among Women with HIV Infection in Harris County, Texas, United States of America. HIV Adv Res Dev (2015) 0.75
Normal levels of vitamin D among HIV-infected Catalan pediatric patients. J Acquir Immune Defic Syndr (2012) 0.75
Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study. BMC Musculoskelet Disord (2013) 0.75
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. Medicine (Baltimore) (2016) 0.75
Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl (2013) 0.75
Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? Nutrients (2017) 0.75
Vitamin D deficiency. N Engl J Med (2007) 59.34
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr (2000) 11.69
25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med (2008) 8.03
Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr (2008) 7.61
Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr (2002) 7.34
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med (2008) 7.21
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int (2006) 7.02
Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med (2009) 6.84
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Update in vitamin D. J Clin Endocrinol Metab (2010) 4.48
Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet (1989) 3.77
Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med (2007) 2.95
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis (2005) 2.82
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses (2008) 2.41
Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation (1997) 2.32
Frequency of leisure-time physical activity and serum 25-hydroxyvitamin D levels in the US population: results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol (2008) 2.08
High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses (2009) 2.03
Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis (2011) 2.00
Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One (2010) 1.91
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther (2010) 1.83
Vitamin D, race, and cardiovascular mortality: findings from a national US sample. Ann Fam Med (2010) 1.72
Vitamin d, adiposity, and calcified atherosclerotic plaque in african-americans. J Clin Endocrinol Metab (2010) 1.64
Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr (2006) 1.49
Efavirenz and bone health. AIDS (2009) 1.11
The noncalciotropic actions of vitamin D: recent clinical developments. Curr Opin Nephrol Hypertens (2008) 1.04
Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis (2010) 1.03
Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton) (2008) 1.02
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS (2006) 0.99
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
A piece of my mind. Winners and losers. JAMA (2004) 5.59
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer (2008) 2.30
Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis (2002) 2.29
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis (2008) 1.99
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Factors associated with use of dental services among HIV-infected and high-risk uninfected women. J Am Dent Assoc (2005) 1.79
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis (2008) 1.67
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS (2014) 1.66
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Timing of repeat colonoscopy: disparity between guidelines and endoscopists' recommendation. Am J Prev Med (2007) 1.53
The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica (2006) 1.53
Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972-2005: A report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.52
Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.50
Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend (2007) 1.50
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause (2015) 1.49
Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. JPEN J Parenter Enteral Nutr (2002) 1.49
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res (2005) 1.49
Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol (2007) 1.48
Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol (2002) 1.47
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Characteristics of Early Recipients of Patient-Centered Outcomes Research Institute Funding. Acad Med (2016) 1.44
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS (2013) 1.43
Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health (2009) 1.43
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer (2008) 1.40
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (2010) 1.37
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr (2012) 1.37
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS (2009) 1.36
Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol (2010) 1.36
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol (2006) 1.35
Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr (2008) 1.34
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.31
Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS Behav (2007) 1.31
Obesity and immune cell counts in women. Metabolism (2007) 1.31
CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis (2003) 1.29
Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS (2010) 1.29
Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend (2007) 1.28
Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management. AIDS (2003) 1.28
Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS (2009) 1.25
Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (2008) 1.24
The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med (2009) 1.23
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr (2008) 1.22
Solanum nigrum: current perspectives on therapeutic properties. Altern Med Rev (2011) 1.22
Fractures after antiretroviral initiation. AIDS (2012) 1.21
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21